Insmed reported $524.42M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
DBV Technologies USD 1.6M 955K Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 524.42M 98.93M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026